ArticleScientific reports2019
Genomic characterization of an emerging bla
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Inference of antimicrobial resistance (AMR) from a whole genome database outperforming AMR gene detection.iScience · 2025Article
- First report on comprehensive genomic analysis of a multidrug-resistant Enterobacter asburiae isolated from diabetic foot infection from Bangladesh.Scientific reports · 2025Article
- Detection of clinicalHeliyon · 2024Article
- Clinically relevant antibiotic resistance inmSphere · 2023Article
- Klebsiella pneumoniae carbapenamases in Escherichia coli isolated from humans and livestock in rural south-western Uganda.PloS one · 2023Article
- Multiplex PCR Detection of Common Carbapenemase Genes and Identification of Clinically RelevantAntibiotics (Basel, Switzerland) · 2022Article
- Antimicrobial resistance and genetic background of non-typhoidal Salmonella enterica strains isolated from human infections in São Paulo, Brazil (2000-2019).Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Article
- Multi Evaluation of a Modified GoldNano Carb Test for Carbapenemase Detection in Clinical Isolates of Gram-Negative Bacilli.Antibiotics (Basel, Switzerland) · 2022Article
- Synergistic Antibacterial Effects of Meropenem in Combination with Aminoglycosides against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Genomic Characterization of Clinical Extensively Drug-ResistantMicroorganisms · 2021Article
- Antibiotic Resistance Genes Among Carbapenem-resistant Enterobacterales (CRE) Isolates of Prapokklao Hospital, Chanthaburi Province, Thailand.Infection and drug resistance · 2021Article
- Epidemic Characteristics of Carbapenem-ResistantInfection and drug resistance · 2020Article
- Whole-Genome Sequencing of Clinically Isolated Carbapenem-Resistant Enterobacterales HarboringFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rapidly increasing prevalence of carbapenem-resistant Enterobacteriaceae (CRE) over the past decade has increased concern in healthcare facilities and the impact on public health. The prevalence of bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.